These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37216304)

  • 1. POLE exonuclease domain mutations in endometrial carcinoma: a case report.
    Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E
    Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
    Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ
    Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
    Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
    J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
    Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
    Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
    Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
    Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
    Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
    Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
    McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
    Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
    Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
    Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
    Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.